Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.

James R, Thriveni K, Krishnamoorthy L, Deshmane V, Bapsy PP, Ramaswamy G.

Indian J Med Res. 2011 Jan;133:70-5.

2.

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W.

Cancer. 2005 Jul 15;104(2):257-63.

3.

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.

Clin Cancer Res. 1998 Jan;4(1):7-12.

4.

Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.

Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W.

J Clin Oncol. 2003 May 15;21(10):1967-72.

PMID:
12743150
5.

HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.

Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.

Anticancer Res. 2006 Jan-Feb;26(1B):647-53.

6.

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID:
12529347
8.
9.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
10.

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R.

J Natl Cancer Inst. 2003 Mar 5;95(5):353-61.

PMID:
12618500
12.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

13.

Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.

Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K; Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group.

Breast Cancer Res Treat. 2003 Aug;80(3):245-55.

PMID:
14503797
14.
15.

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.

Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC.

J Clin Oncol. 2003 Feb 1;21(3):453-7.

PMID:
12560434
16.

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L.

J Clin Oncol. 2000 Oct 15;18(20):3471-9.

PMID:
11032587
17.

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.

J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.

PMID:
16682728
18.

Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

Ciocca DR, Gago FE, Fanelli MA, Calderwood SK.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):32-40. Epub 2006 Oct 17. Review.

PMID:
17049840
19.

Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).

Corte MD, Rodil JA, Vázquez J, García L, Rodríguez JC, Bongera M, Fernández JC, González LO, Lamelas ML, Allende M, García-Muñiz JL, Fueyo A, Vizoso FJ.

J Cancer Res Clin Oncol. 2005 Nov;131(11):701-14. Epub 2005 Nov 1.

PMID:
16075281
20.

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD.

Clin Cancer Res. 2004 Mar 1;10(5):1706-16.

Supplemental Content

Support Center